Corlentor

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

ivabradine hydrochloride

Available from:

Les Laboratoires Servier

ATC code:

C01EB17

INN (International Name):

ivabradine

Therapeutic group:

CARDIAC THERAPY

Therapeutic area:

Angina Pectoris; Heart Failure

Therapeutic indications:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Product summary:

Revision: 26

Authorization status:

Authorised

Authorization date:

2005-10-25

Patient Information leaflet

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CORLENTOR 5 MG FILM-COATED TABLETS
CORLENTOR 7.5 MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Corlentor is and what it is used for
2.
What you need to know before you take Corlentor
3.
How to take Corlentor
4.
Possible side effects
5
How to store Corlentor
6.
Contents of the pack and other information
1.
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute.
It is used in adult patients who do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most common s
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Corlentor 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Corlentor 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Corlentor 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Corlentor 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated :
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
Treatment of chronic heart failure
3
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the decision to ini
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-10-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-10-2021
Public Assessment Report Public Assessment Report Bulgarian 25-02-2019
Patient Information leaflet Patient Information leaflet Spanish 12-10-2021
Public Assessment Report Public Assessment Report Spanish 25-02-2019
Patient Information leaflet Patient Information leaflet Czech 12-10-2021
Public Assessment Report Public Assessment Report Czech 25-02-2019
Patient Information leaflet Patient Information leaflet Danish 12-10-2021
Public Assessment Report Public Assessment Report Danish 25-02-2019
Patient Information leaflet Patient Information leaflet German 12-10-2021
Public Assessment Report Public Assessment Report German 25-02-2019
Patient Information leaflet Patient Information leaflet Estonian 12-10-2021
Public Assessment Report Public Assessment Report Estonian 25-02-2019
Patient Information leaflet Patient Information leaflet Greek 12-10-2021
Public Assessment Report Public Assessment Report Greek 25-02-2019
Patient Information leaflet Patient Information leaflet French 12-10-2021
Public Assessment Report Public Assessment Report French 25-02-2019
Patient Information leaflet Patient Information leaflet Italian 12-10-2021
Public Assessment Report Public Assessment Report Italian 25-02-2019
Patient Information leaflet Patient Information leaflet Latvian 12-10-2021
Public Assessment Report Public Assessment Report Latvian 25-02-2019
Patient Information leaflet Patient Information leaflet Lithuanian 12-10-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-10-2021
Public Assessment Report Public Assessment Report Lithuanian 25-02-2019
Patient Information leaflet Patient Information leaflet Hungarian 12-10-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 12-10-2021
Public Assessment Report Public Assessment Report Hungarian 25-02-2019
Patient Information leaflet Patient Information leaflet Maltese 12-10-2021
Public Assessment Report Public Assessment Report Maltese 25-02-2019
Patient Information leaflet Patient Information leaflet Dutch 12-10-2021
Public Assessment Report Public Assessment Report Dutch 25-02-2019
Patient Information leaflet Patient Information leaflet Polish 12-10-2021
Public Assessment Report Public Assessment Report Polish 25-02-2019
Patient Information leaflet Patient Information leaflet Portuguese 12-10-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 12-10-2021
Public Assessment Report Public Assessment Report Portuguese 25-02-2019
Patient Information leaflet Patient Information leaflet Romanian 12-10-2021
Public Assessment Report Public Assessment Report Romanian 25-02-2019
Patient Information leaflet Patient Information leaflet Slovak 12-10-2021
Public Assessment Report Public Assessment Report Slovak 25-02-2019
Patient Information leaflet Patient Information leaflet Slovenian 12-10-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 12-10-2021
Public Assessment Report Public Assessment Report Slovenian 25-02-2019
Patient Information leaflet Patient Information leaflet Finnish 12-10-2021
Public Assessment Report Public Assessment Report Finnish 25-02-2019
Patient Information leaflet Patient Information leaflet Swedish 12-10-2021
Public Assessment Report Public Assessment Report Swedish 25-02-2019
Patient Information leaflet Patient Information leaflet Norwegian 12-10-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 12-10-2021
Patient Information leaflet Patient Information leaflet Icelandic 12-10-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 12-10-2021
Patient Information leaflet Patient Information leaflet Croatian 12-10-2021
Public Assessment Report Public Assessment Report Croatian 25-02-2019

Search alerts related to this product

View documents history